III2022-006
TRANSLATIONAL G.I. IN CELLULAR IMMUNOLOGY (GITIC)
Infectious, inflammatory and immune-mediated diseases area.
Objectives and lines of research
– The Translational Research Group in Cellular Immunology (GITIC) focuses on the study of the antigen-specific cytotoxic T cell response depleted in chronic viral infections and cancer. This group has studied this type of response in chronic HBV, HCV, HIV and hepatocarcinoma infection.
– Currently, our group is interested in the characterization of the metabolic phenotype of the virus-specific CD8 progenitor population in HIV and HBV infection.
– In addition, we are interested in other translational aspects derived from the study of this response, such as defining a treatment stopping rule in chronic HBV hepatitis, based on the characteristics of the CD8+ HBV-specific response and serological biomarkers. We are also working on cellular markers that allow rapid differentiation between chronic HBV hepatitis and chronic HBV infection.
– Our group addresses issues of delayed diagnosis, missed opportunities, advanced HIV disease (CD4 lymphocytes < 200 cells/mcL), classical opportunistic infections and different antiretroviral treatments.
– The group also participates in various expert panels for the development of national clinical practice guidelines.
– Currently, our group is interested in the characterization of the metabolic phenotype of the virus-specific CD8 progenitor population in HIV and HBV infection.
– In addition, we are interested in other translational aspects derived from the study of this response, such as defining a treatment stopping rule in chronic HBV hepatitis, based on the characteristics of the CD8+ HBV-specific response and serological biomarkers. We are also working on cellular markers that allow rapid differentiation between chronic HBV hepatitis and chronic HBV infection.
– Our group addresses issues of delayed diagnosis, missed opportunities, advanced HIV disease (CD4 lymphocytes < 200 cells/mcL), classical opportunistic infections and different antiretroviral treatments.
– The group also participates in various expert panels for the development of national clinical practice guidelines.
Research team
- JUAN RAMÓN LARRUBIA MARFIL
- MIGUEL TORRALBA GONZÁLEZ DE SUSO
- HENAR CALVO SÁNCHEZ
- JOAQUÍN MIQUEL PLAZA
- EDUARDO SANZ-DE-VILLALOBOS
- ALEJANDRO GONZÁLEZ-PRAETORIUS
- JULIA PEÑA ASENSIO
- JENIFFER DE LA CARIDAD MARTÍNEZ GONZÁLEZ
- ALBERTO DELGADO FERNÁNDEZ
Responsible
JUAN RAMÓN LARRUBIA MARFIL
MIGUEL TORRALBA GONZÁLEZ DE SUSO
IPs
JUAN RAMÓN LARRUBIA MARFIL
MIGUEL TORRALBA GONZÁLEZ DE SUSO
FINCA DE LA PERALEDA, S/N. 45071. Toledo
Developed by Nexora